

July 4, 2022

Company: Chiome Bioscience Inc.
Representative: Shigeru Kobayashi, President & CEO
(Code: 4583, Tokyo Stock Exchange Growth)

**First patient in of cancer therapeutic antibody CBA-1535
in a Phase 1 clinical trial**

Chiome Bioscience Inc. announced today that the first patient has been dosed CBA-1535 in a Phase I clinical trial.

The first part of the trial will evaluate the safety, tolerability, pharmacokinetics, and identification of biomarker for the solid tumor patients. In the expansion part, exploratory efficacy will be evaluated in combination with cancer immunotherapy agent Pembrolizumab. This first-in-human study is conducted at National Cancer Center Hospital and Shizuoka Cancer Center. We will continue to update the future process in a timely manner.

There is no impact on the financial performance in the fiscal period ending December 31, 2022.

< About CBA-1535 >

CBA-1535 is cancer therapeutic antibody with three antigen binding sites; two of them are used for the binding with 5T4 protein that expresses multiple type of solid tumor, and one is for the binding with CD3 protein on the surface of immune T cells. CBA-1535 is anticipated to have strong cytotoxicity arisen from T cell proliferation and activation. CBA-1535 is targeted for refractory cancer such as malignant mesothelioma, small cell lung cancer, and non-small cell lung cancer and for solid tumor such as kidney, ovarian, and breast cancer.

【Inquiries】

Chiome Bioscience Inc. Investor Relations
E-mail: ir@chiome.co.jp